2098488-36-7 Usage
Uses
Given the provided materials, there are no specific applications mentioned for N-(4-azidobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide. However, based on its complex structure and the functional groups it contains, we can hypothesize potential uses in the following industries:
Used in Pharmaceutical Industry:
N-(4-azidobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide could be used as a pharmaceutical intermediate or a lead compound for the development of new drugs. Its complex structure and functional groups may provide opportunities for medicinal chemists to explore its potential in treating various diseases or conditions.
Used in Chemical Research:
As a complex chemical compound, N-(4-azidobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide may be used in chemical research to study its reactivity, stability, and interactions with other molecules. This could lead to a better understanding of its properties and potential applications in various chemical processes.
Used in Material Science:
The presence of azide, amide, and aromatic rings in the compound suggests that it may have unique properties that could be exploited in the development of new materials. For example, it could be used as a component in the synthesis of polymers, coatings, or other materials with specific properties, such as improved stability, reactivity, or selectivity.
Check Digit Verification of cas no
The CAS Registry Mumber 2098488-36-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,0,9,8,4,8 and 8 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 2098488-36:
(9*2)+(8*0)+(7*9)+(6*8)+(5*4)+(4*8)+(3*8)+(2*3)+(1*6)=217
217 % 10 = 7
So 2098488-36-7 is a valid CAS Registry Number.
2098488-36-7Relevant academic research and scientific papers
Traceless Staudinger ligation enabled parallel synthesis of proteolysis targeting chimera linker variants
Bemis, Troy A.,La Clair, James J.,Burkart, Michael D.
, p. 1026 - 1029 (2021/02/06)
A parallel, one-pot assembly approach to proteolysis targeting chimeras (PROTACs) is demonstrated utilizing activated esters generatedin situ, and traceless Staudinger ligation chemistry. The method described allows for rapid structure-activity relationship studies of PROTAC linker variants. Two previously studied systems, cereblon and BRD4 degraders, are examined as test cases for the synthetic method. The two related strategies to assemble PROTAC linker variants discussed can accommodate the chromotographic separations capabilities of labs of many sizes and incorporates commercially available degrader building blocks, thereby easing synthetic entry into PROTAC chemical space.
Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals)
Schiedel, Matthias,Herp, Daniel,Hammelmann, S?ren,Swyter, S?ren,Lehotzky, Attila,Robaa, Dina,Oláh, Judit,Ovádi, Judit,Sippl, Wolfgang,Jung, Manfred
, p. 482 - 491 (2018/02/07)
Here we report the development of a proteolysis targeting chimera (PROTAC) based on the combination of the unique features of the sirtuin rearranging ligands (SirReals) as highly potent and isotype-selective Sirt2 inhibitors with thalidomide, a bona fide
